Credit Suisse Ag Vanda Pharmaceuticals Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$4.28 - $6.57 $55,010 - $84,444	-12,853 Reduced 18.18%	57,864 $249,000
Q2 2023 Aug 11, 2023	BUY	$5.9 - $6.95 $125,994 - $148,417	21,355 Added 43.26%	70,717 $466,000
Q1 2023 May 10, 2023	BUY	$6.18 - $7.99 $92 - $119	15 Added 0.03%	49,362 $335,000
Q4 2022 Feb 13, 2023	SELL	$6.87 - $10.96 $54,801 - $87,427	-7,977 Reduced 13.92%	49,347 $364,000
Q3 2022 Nov 10, 2022	BUY	$9.44 - $11.76 $3,039 - $3,786	322 Added 0.56%	57,324 $566,000
Q2 2022 Aug 12, 2022	SELL	$9.31 - $11.84 $32,417 - $41,226	-3,482 Reduced 5.76%	57,002 $621,000
Q1 2022 May 16, 2022	SELL	$10.84 - $16.55 $9,940 - $15,176	-917 Reduced 1.49%	60,484 $684,000
Q4 2021 Feb 14, 2022	BUY	$15.69 - $21.14 $3,514 - $4,735	224 Added 0.37%	61,401 $964,000
Q3 2021 Nov 12, 2021	BUY	$15.35 - $21.27 $9,348 - $12,953	609 Added 1.01%	61,177 $1.05 Million
Q2 2021 Aug 16, 2021	SELL	$15.71 - $21.51 $99,255 - $135,900	-6,318 Reduced 9.45%	60,568 $1.3 Million
Q1 2021 May 14, 2021	SELL	$13.42 - $20.28 $289,590 - $437,622	-21,579 Reduced 24.39%	66,886 $1.01 Million
Q4 2020 Feb 12, 2021	SELL	$9.77 - $13.81 $177,364 - $250,706	-18,154 Reduced 17.03%	88,465 $1.16 Million
Q3 2020 Nov 13, 2020	SELL	$9.32 - $12.02 $85,380 - $110,115	-9,161 Reduced 7.91%	106,619 $1.03 Million
Q2 2020 Aug 12, 2020	BUY	$9.66 - $12.02 $751,760 - $935,420	77,822 Added 205.02%	115,780 $1.33 Million
Q1 2020 May 13, 2020	SELL	$7.5 - $16.8 $67,575 - $151,368	-9,010 Reduced 19.18%	37,958 $393,000
Q4 2019 Feb 12, 2020	BUY	$12.38 - $17.47 $111,308 - $157,072	8,991 Added 23.67%	46,968 $770,000
Q3 2019 Nov 12, 2019	SELL	$12.27 - $15.79 $124,540 - $160,268	-10,150 Reduced 21.09%	37,977 $504,000
Q2 2019 Aug 14, 2019	SELL	$13.37 - $18.85 $311,066 - $438,564	-23,266 Reduced 32.59%	48,127 $678,000
Q1 2019 May 14, 2019	BUY	$17.59 - $31.05 $518,060 - $914,484	29,452 Added 70.22%	71,393 $1.31 Million
Q4 2018 Feb 13, 2019	BUY	$18.97 - $31.47 $232,742 - $386,105	12,269 Added 41.35%	41,941 $1.1 Million
Q3 2018 Nov 13, 2018	SELL	$18.25 - $23.0 $608,254 - $766,567	-33,329 Reduced 52.9%	29,672 $680,000
Q2 2018 Aug 14, 2018	BUY	$13.95 - $19.15 $226,589 - $311,053	16,243 Added 34.74%	63,001 $1.2 Million
Q1 2018 May 15, 2018	BUY	$14.05 - $20.2 $76,305 - $109,706	5,431 Added 13.14%	46,758 $788,000
Q4 2017 Feb 14, 2018	SELL	$12.85 - $18.1 $158,684 - $223,516	-12,349 Reduced 23.01%	41,327 $628,000
Q3 2017 Nov 14, 2017	BUY	$15.4 - $18.85 $137,706 - $168,556	8,942 Added 19.99%	53,676 $961,000
Q2 2017 Aug 14, 2017	BUY	N/A	44,734	44,734 $729,000

Others Institutions Holding VNDA

# of Institutions

161

Shares Held

45.2M

Call Options Held

165K

Put Options Held

33.6K

Black Rock Inc. New York, NY

8.14M
Shares

$39.5 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

4.01M
Shares

$19.5 Million
0.03% of portfolio
Vanguard Group Inc Valley Forge, PA

3.63M
Shares

$17.6 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

2.35M
Shares

$11.4 Million
0.94% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.26M
Shares

$11 Million
0.0% of portfolio

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $274M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account